Patents Examined by Sudhakar Katakam
  • Patent number: 10383918
    Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, includes at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions include, in addition, a gastrointestinal hormone.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: August 20, 2019
    Assignee: ADOCIA
    Inventors: Alexandre Geissler, Ségolène Laage, Olivier Soula, David Duracher, Grégory Meiffren
  • Patent number: 10383920
    Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, including at least: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: August 20, 2019
    Assignee: ADOCIA
    Inventors: Alexandre Geissler, Ségolène Laage, Richard Charvet, Olivier Soula
  • Patent number: 10377693
    Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: August 13, 2019
    Assignee: Zhejiang Ausun Pharmaceutical Co., Ltd.
    Inventors: Junbiao Chang, Chuanjun Song
  • Patent number: 10363258
    Abstract: Provided herein are prostaglandin F2? analog compositions and methods for treating migraines.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 30, 2019
    Assignee: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Patent number: 10351545
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula (1a) or a salt thereof, wherein p, q, r, s, Q, R3 and R4 are as defined herein.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 16, 2019
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Patent number: 10344052
    Abstract: Provided are peptides, fusion proteins which include the peptide sequences, compositions comprising such peptides and fusion proteins, and methods for making and using the compositions. The peptides are characterized as being able to selectively bind to components of the endothelial compartment that are exposed during the period between 1 and 7 days after androgen deprivation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 9, 2019
    Assignee: Health Research, Inc.
    Inventors: Gary Smith, Ryan Willard
  • Patent number: 10335382
    Abstract: In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-?-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: July 2, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Mark Hellmich, Jia Zhou, Csaba Szabo
  • Patent number: 10335388
    Abstract: The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 2, 2019
    Assignee: PELOTON THERAPEUTICS, INC.
    Inventors: John A. Josey, Eli M. Wallace, Guangzhou Han
  • Patent number: 10335431
    Abstract: A method for preparing polycondensation products of guanidine, aminoguanidine or diaminoguanidine G with one or more benzyl or allyl derivatives BA according to the following reaction scheme is provided: wherein X, R1, Gua, Y and Z are as defined in the specification. In the disclosed method, at least one benzyl or allyl derivative BA is subjected to a polycondensation reaction with excessive guanidine, aminoguanidine or diaminoguanidine G upon elimination of HX.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 2, 2019
    Assignee: Sealife Pharma GmbH
    Inventors: Alexander Pretsch, Michael Nagl, Christoph Wiesner, Ralph Hollaus, Miroslav Genov
  • Patent number: 10329239
    Abstract: Systems and method are provided for reducing the water content from approximately 0.15%-0.19% by weight to approximately 0.01-0.03% by weight in an ethanolamine product stream in a non-reactive distillation column. The reduced water content can be achieved by increasing the processing conditions at the drying column by approximately 5% to approximately 20%, more preferably to approximately 10%. The increased processing conditions at the drying column can result in an increased bottom stream flow rate and an increased reboiler duty. The reboiler duty of the drying column can be increased by up to 2% to achieve said level of water content. The bottom stream flow rate can be increased by up to approximately 12% to achieve said level of water content.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: June 25, 2019
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V
    Inventor: Naeem Al-Hazmi
  • Patent number: 10329238
    Abstract: A method for isomerizing a starting mixture comprising 2,4-diamino-1-methylcyclohexane, 2,4-MDACH for short, 2,6-diamino-1-methylcyclohexane, 2,6-MDACH for short, or mixtures thereof, wherein the isomerization is carried out in the presence of a supported catalyst with zirconium dioxide as support and ruthenium as active metal.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 25, 2019
    Assignee: BASF SE
    Inventors: Andreas Weickgenannt, Sandra Kramp, Jan-Oliver Weidert, Alexander Panchenko, Artur Kozicki, Ralph Busch
  • Patent number: 10329237
    Abstract: The present invention relates to a method for hydrogenating aromatic compounds with hydrogen in the presence of a catalyst, in which the catalyst comprises ruthenium on a zirconium oxide support material, and also the use of a catalyst comprising ruthenium on a zirconium oxide support material for hydrogenating aromatic compounds.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: June 25, 2019
    Assignee: BASF SE
    Inventors: Bernd Bastian Schaack, Martin Bock, Kirsten Dahmen
  • Patent number: 10314835
    Abstract: This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder. In certain embodiments, the neurokinin 3 receptor antagonist is (R)—N-{{3-[1-Benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1-yl}-4-phenylpiperidin-4-yl}-N-methylacetamine or salts thereof.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 11, 2019
    Assignee: Emory University
    Inventors: Kerry J. Ressler, Raul Andero Gali
  • Patent number: 10308590
    Abstract: Systems and methods for producing a colorless triethanolamine product stream with a degree of purity of greater than or equal to 99% by weight from the triethanolamine distillation columns in a non-reactive distillation process. The desired triethanolamine product stream can be obtained by increasing the bottom stream flow rate at the diethanolamine column by 80 kilograms per hour, and reducing the triethanolamine product stream flow rate by 500 kilograms per hour. This process can result in a reduction of the temperature at the triethanolamine column by up to 23.5 degrees. The reduced temperature can result in a triethanolamine product stream with an APHA color of 0 to less than 50, for example, 0 to 40, for example, 0 to 30, for example 0 to 20, and for example, 0 to 10.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: June 4, 2019
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V.
    Inventor: Naeem Alhazmi
  • Patent number: 10307393
    Abstract: The present invention provides applications of a small molecular flavonoid compound in preparing a medication for sensitizing/synergizing tumor radiation therapy as well as reducing radioactive damage. The small molecular flavonoid compound can be naringenin, hesperetin, luteolin and apigenin, etc. The medication contains a small molecular flavonoid compound and a plurality of conventional pharmaceutical additives; wherein the small molecular flavonoid compound is an active ingredient.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 4, 2019
    Assignees: INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES, TOPFOND PHARMACEUTICAL CO., LTD.
    Inventors: Wei Liang, Chun Ling Zhang, Wen Feng Zeng, Chao Zhang, Luo Yang Wang
  • Patent number: 10307388
    Abstract: Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: June 4, 2019
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Stephanie Kay Venn-Watson
  • Patent number: 10301279
    Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 28, 2019
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
  • Patent number: 10301297
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 28, 2019
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • Patent number: 10287308
    Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: May 14, 2019
    Assignee: PLACON THERAPEUTICS, INC.
    Inventors: Mark T. Bilodeau, Benoît Moreau
  • Patent number: 10278942
    Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 7, 2019
    Assignee: Peloton Therapeutics, Inc.
    Inventors: John A. Josey, Eli M. Wallace, Xinlin Du, Barry Goggin